Abstract:In the pivotal HERIZON-BTC-01 study, the HER2 bispecific antibody zani demonstrated rapid, durable responses (confirmed objective response rate, 41% by independent central review; median duration of response, 12.9 mo; data cut-off: Oct 2022) and manageable safety in pts with HER2+ BTC. Here we report QoL outcomes for those pts with HER2+ BTC. HERIZON-BTC-01 (NCT04466891), an ongoing open-label, global phase 2b study, evaluated zani (20 mg/kg IV every 2 wks) in pts with HER2+ (gene amplification with immunohistochemistry of 2+ or 3+), locally advanced, unresectable or metastatic BTC (gallbladder cancer, intra-/extra-hepatic cholangiocarcinoma) who received prior gemcitabine-containing treatment (tx). QoL, an exploratory endpoint, was assessed using the EQ-5D-5L descriptive system and visual analogue scale (VAS) at baseline (BL) and every 8 wks; best on-treatment score (BONT) was the lowest descriptive or highest VAS value observed post-BL. A total of 80 pts with HER2+ BTC were evaluated for primary efficacy analyses (median age, 64 years; 56% female). Of these, 1 (1%) had complete response (CR), 32 (40%) had partial response (PR), 22 (28%) had stable disease (SD) and 24 (30%) had progressive disease (PD); 1 pt was not evaluable. Pts with CR or PR reported the greatest improvement in QoL followed by those with SD, while pts with PD generally reported worsening QoL (Table). Median VAS scores improved by ≥10 points from BL to time of BONT for pts with CR and PR, by 5 points for pts with SD and worsened by 10 points for pts with PD. In each dimension, the proportion of pts reporting ‘no problem’ increased more from BL to BONT for pts with PR than for pts with SD or PD.Table: 101PEQ-5D-5L QoL outcomes in pts with HER2+ BTC by tumour responseConfirmed Best Overall Tumour ResponseCRPRSDPDBLBONTBLBONTBLBONTBLBONTn=1n=1n=31n=32n=21n=22n=24n=19Median VAS score4080809580888070Median VAS change from BLa40105-10Least severe response level (no problem), n (%)Mobility0023 (74)30 (94)16 (76)19 (86)15 (63)12 (63)Self-care0028 (90)31 (97)18 (86)19 (86)23 (96)16 (84)Usual activities0023 (74)29 (91)11 (52)15 (68)16 (67)10 (53)Pain/discomfort01 (100)15 (48)28 (88)10 (48)13 (59)10 (42)7 (37)Anxitey/depression0018 (58)28 (88)12 (57)14 (64)13 (54)14 (74)aOut of pts with a BL and ≥1 post-BL score Open table in a new tab aOut of pts with a BL and ≥1 post-BL score In HERIZON-BTC-01, pts with HER2+ BTC who responded to zani reported improved QoL compared with BL, while those with PD reported worsening QoL compared with BL. These results support the continuing development of zani as a HER2+ BTC tx option.

101P Quality of Life (qol) Outcomes in Patients (pts) with Zanidatamab (Zani)-Treated HER2-positive (HER2+) Biliary Tract Cancer (BTC) in the Phase IIb HERIZON-BTC-01 Study